论文瑞舒伐他汀用于缺血性脑卒中二级预防疗效安全性是关于他汀方面的的相关大学硕士和相关本科毕业论文以及相关阿托伐和瑞舒伐哪个好论文开题报告范文和职称论文写作参考文献资料下载。
[摘 要] 目的 探究應用瑞舒伐他汀治疗缺血性脑卒中二级预防的临床疗效及安全性. 方法 方便选取该院2015年10月—2016年12月期间诊治的80例缺血性脑卒中合并高血脂症患者为研究对象,将患者随机分为观察组和对照组,每组40例.观察组患者采用瑞舒伐他汀治疗,对照组患者采用阿托伐他汀治疗,连续治疗12周后比较2组患者降脂疗效和安全性. 结果 通过比较发现,两组患者治疗后TC、TG及LDL-C水平均显著降低,观察组患者TC（4.92±0.11）mmol/L,TG（1.84±0.09）mmol/L,LDL-C（2.42±0.08）mmol/L,HDL-C（1.02±0.08）mmol/L,对照组患者TC（5.21±0.15）mmol/L,TG（1.98±0.16）mmol/L,LDL-C（3.02±0.15）mmol/L,HDL-C（0.95±0.06）mmol/L,观察组降低效果优于对照组患者（P<0.05）；对比2组患者临床降脂效果,观察组患者中显效11例,有效9例,无效1例,无恶化患者,对照组患者中显效6例,有效9例,无效4例,观察组优于对照组（P<0.05）；比较两组患者的不良反应发生率,观察组患者不良反应率为4.76%,对照组患者不良反应率为14.28%,观察组优于对照组（P<0.05）. 结论 在缺血性脑卒中患者的二级预防中应用瑞舒伐他汀具有积极的临床效果,安全可靠,值得推广.
[关键词] 缺血性脑卒中；瑞舒伐他汀；二级预防；安全性
[中图分类号] R5 [文献标识码] A [文章编号] 1674-0742（2017）10（b）-0115-03
[Abstract] Objective This paper tries to explore the clinical efficacy and safety of rosuvastatin in the prevention of secondary prevention of ischemic stroke. Methods 80 cases of ischemic stroke with hyperlipidemia treated in this hospital from October 2015 to December 2016 were convenient selected and were randomly divided into the observation group and the control group, with 40 cases in each group. The patients in the observation group were treated with rosuvastatin and the control group was treated with atorvastatin. After 12 weeks of continuous treatment, the efficacy and safety of lipid reduction were compared between the two groups. Results After comparison, the level of TC, TG and LDL-C of both groups decreased after treatment, and TC was （4.92±0.11）mmol/L, TG was （1.84±0.09）mmol/L, LDL-C was （2.42±0.08）mmol/L, HDL-C was （1.02±0.08）mmol/L in the observation group, and TC was （5.21±0.15）mmol/L, TG was （1.98±0.16）mmol/L, LDL-C was（3.02±0.15）mmol/L, HDL-C was（0.95±0.06）mmol/L in the control group, the decrease level of the observation group was better than the control group（P<0.05）； from the comparison of lipid-lowering of both groups, in the observation group, 11 cases were markedly effective, 9 cases were effective, 1 case was ineffective, no deterioration； in the control group, 6 cases were markedly effective, 9 cases were effective, 4 cases were ineffective, therefore the observation group was better than the control group（P<0.05）. By the comparison of the adverse events rate of both groups, the adverse reaction rate was 4.76% in the observation group and 14.28% in the control group. The observation group was better than the control group （P<0.05）. Conclusion The use of rosuvastatin in the secondary prevention of ischemic stroke has a positive clinical effect, safe and reliable, and it is worthy of promotion.
总结:本文关于他汀论文范文,可以做为相关论文参考文献,与写作提纲思路参考。
参考文献：
1、 39例毛南族青年缺血性脑卒中全脑血管造影分析 【摘要】目的探究毛南族青年缺血性脑卒中脑血管造影的诊断价值。方法回顾性分析近年来收治的39例毛南族青年缺血性脑卒中患者资料，对患者主动脉弓、颈总。
2、 不同剂量辛伐他汀治疗急性脑梗死的临床效果观察 【摘要】 目的 研究不同剂量辛伐他汀治疗急性脑梗死的效果。方法 60例急性脑梗死患者， 按照随机数字表法分为实验组和参照组， 各30例。所有患者。
3、 缺血性脑卒中糖尿病患者综合护理干预效果分析 [摘要] 目的 分析缺血性脑卒中糖尿病患者的综合护理干预及效果。方法 资料选取该院2015年8月—2016年8月治疗的105例缺血性脑卒中糖尿病。
4、 对析瑞舒伐他汀和阿托伐他汀治疗冠心病临床疗效 DOI：10 16662 j cnki 1674-0742 2017 07 094[摘要] 目的 对比分析瑞舒伐他汀与阿托伐他汀治疗冠心病的临。
5、 瑞舒伐他汀和阿托伐他汀治疗冠心病疗效对比 [摘要] 目的 探讨对冠心病患者采取同等剂量的瑞舒伐他汀和阿托伐他汀进行治疗的疗效。方法 方便选取该院冠心病患者104例（2015年1月—201。
6、 瑞舒伐他汀对老年高血压患者血脂水平PWV治疗分析 [摘要] 目的 通过研究评价瑞舒伐他汀对老年高血压并存脂代谢异常的患者血脂及脉搏波传导速度（pulse wave velocity，PWV）的治。